NCT04560816View on ClinicalTrials.gov

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

March 24, 2021

Study Completion Date

March 24, 2021

Conditions
Healthy
Interventions
DRUG

ALXN1840

ALXN1840 (120 milligrams) will be administered orally (supratherapeutic dose).

DRUG

Placebo

Placebo will be administered orally.

DRUG

Moxifloxacin

Moxifloxacin (400 milligrams) will be administered orally.

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Collaborators (1)

PPD Development, LP
All Listed Sponsors
collaborator

PPD Development, LP

INDUSTRY

collaborator

ERT: Clinical Trial Technology Solutions

OTHER

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY